Core Insights - The article discusses the current market trends and potential investment opportunities within specific sectors, highlighting the importance of thorough analysis before making investment decisions [2]. Group 1: Market Trends - Recent market fluctuations have shown a significant impact on investor sentiment, with many turning to defensive stocks as a safe haven during periods of uncertainty [2]. - The technology sector continues to demonstrate resilience, with several companies reporting strong earnings growth despite broader economic challenges [2]. Group 2: Investment Opportunities - Analysts suggest that companies focusing on sustainable practices are likely to attract more investment as ESG (Environmental, Social, and Governance) criteria become increasingly important to investors [2]. - There is a growing interest in healthcare stocks, particularly those involved in innovative treatments and technologies, as the sector is expected to benefit from demographic trends and increased healthcare spending [2].

Key Takeaways MMSI's $22M C2 CryoBalloon deal broadens GI portfolio, targeting Barrett's esophagus treatment growth.MMSI expects $6-$8M in 2026 revenues from C2 CryoBalloon, despite near-term EPS dilution through 2025-26.MMSI strengthens GI market presence with innovative ablation tech, enhancing long-term growth outlook.Merit Medical Systems (MMSI) announced that it has signed a definitive agreement to acquire the C2 CryoBalloon technology from Pentax of America, a subsidiary of PENTAX Medical, Inc. The in ...

FAR HILLS, N.J.--(BUSINESS WIRE)-- #AMD--Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®). ...

Core Insights - Boston Scientific (BSX) is set to report its third-quarter 2025 results on October 22, with expectations of strong performance based on previous earnings surpassing estimates [1][8] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for BSX's Q3 2025 revenues is $4.97 billion, reflecting an 18.1% increase from the same quarter last year [2] - The consensus estimate for earnings per share (EPS) is 71 cents, indicating a 12.7% growth compared to the prior year's quarter [2][3] Group 2: Performance Drivers - The MedSurg division is expected to maintain solid sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is anticipated to benefit from core franchises and the expanded indication for Rezum, alongside progress from the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends in Deep Brain Stimulation continuing into Q3 [6] - The Cardiovascular segment is projected to perform well, with strong contributions from the Interventional Cardiology Therapies unit and the completion of the SoniVie acquisition [8][9] - The Peripheral Interventions unit is expected to show strong performance, bolstered by recent acquisitions and growth in both arterial and venous product lines [12] Group 3: Market Position and Trends - The MedSurg revenues are estimated at $1.70 billion, suggesting a 15% year-over-year increase [7] - Cardiovascular revenues are expected to improve by 19.6% year over year to $3.27 billion [13] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook [15]

THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. As part of the co ...

Good morning. Ulta Beauty, the largest specialty beauty retailer in the U.S., has a new finance chief.Following an external search, the company selected Christopher DelOrefice, who will begin his tenure on Dec. 5; Chris Lialios will continue to serve as interim CFO until then. DelOrefice succeeds former CFO Paula Oyibo, who left the company in June.He joins Ulta Beauty (No. 375 on the Fortune 500) from medical technology company Becton Dickinson & Co., where he has served as EVP and CFO since September 2021 ...

Company Overview - Odyssey Health, Inc. is a medical technology company focused on life-saving medical solutions and aims to create, acquire, and accumulate distinct assets and technologies that provide meaningful medical solutions [6] - Odyssey Medical Devices, Inc. is a wholly owned subsidiary of Odyssey Health, Inc. [6] Product Announcement - Odyssey Health has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a non-invasive test for breast abnormalities [1] - The BreastCheck® test can be performed at home in just 15 minutes, providing immediate results and serving as an effective first-line screening device [2][4] Market Context - The breast cancer diagnostics market is rapidly growing, currently valued in the low tens of billions of dollars, with forecasts to double or more over the next 8-10 years [3] - Early detection has significantly increased breast cancer survival rates, with an estimated 317,000 new cases of invasive breast cancer expected to be diagnosed in women in the U.S. this year [3][5] Technology and Regulatory Status - The technology behind BreastCheck® is FDA registered in the U.S. and also registered with relevant regulatory authorities in the European Union and the United Kingdom [2] - BreastCheck® is designed to be an adjunct to established procedures for breast disease detection, such as clinical breast examinations and mammography [4] Future Outlook - The company expects to begin commercialization and generate initial revenue from BreastCheck® in the near future, marking a transition from a development-stage to a revenue-generating medtech company [3]

First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its Commercial Leadership Team as it Remains On Track to Commence the Launch of The LIBERTY® SystemDuring Q4 of This Year HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, today announced that it will ...

- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, to m ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued their strength in the third quarter, ending the period with double-digit year-to-date gains. In the quarter, the fund’s Investor Class fund ARTMX returned 8.80%, Advisor Class fund APDMX posted a return of 8.80%, and Institutional Class fund APHMX returned 8.83%, compared to a 2.78% return for the Russell Midc ...